Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro.
about
CMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytesCytomegalovirus antivirals and development of improved animal modelsAdvances in antivirals for non-influenza respiratory virus infections.Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitroComparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro.Antiproliferative effects of octadecyloxyethyl 9-[2-(phosphonomethoxy)ethyl]guanine against Me-180 human cervical cancer cells in vitro and in vivo.Mouse adenovirus type 1 infection in SCID mice: an experimental model for antiviral therapy of systemic adenovirus infections.Acyclic nucleoside phosphonates: a key class of antiviral drugs.Activities of alkoxyalkyl esters of cidofovir (CDV), cyclic CDV, and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against orthopoxviruses in cell monolayers and in organotypic culturesDevelopment of CMX001 for the Treatment of Poxvirus Infections.Alkoxyalkyl esters of (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine are potent inhibitors of the replication of wild-type and drug-resistant human immunodeficiency virus type 1 in vitro.Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate.Update on new antivirals under development for the treatment of double-stranded DNA virus infectionsA fully replication-competent adenovirus vector with enhanced oncolytic propertiesEffect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in miceRecovery of humoral immunity is critical for successful antiviral therapy in disseminated mouse adenovirus type 1 infection.Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal modelNew drug on the horizon for treating adenovirusSerine peptide phosphoester prodrugs of cyclic cidofovir: synthesis, transport, and antiviral activityAlkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivoAlkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art.Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides.Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro.Viral pneumonias in immunocompromised adult hosts.How I treat adenovirus in hematopoietic stem cell transplant recipientsThe search for new therapies for human cytomegalovirus infections.Prodrug strategies in ocular drug delivery.Highlights in antiviral drug research: antivirals at the horizon.Cidofovir Activity against Poxvirus Infections.An adenoviral vector-based expression and delivery system for the inhibition of wild-type adenovirus replication by artificial microRNAs.Targeted expression of herpes simplex virus thymidine kinase in adenovirus-infected cells reduces virus titers upon treatment with ganciclovir in vitro.Small-molecule screening using a whole-cell viral replication reporter gene assay identifies 2-{[2-(benzoylamino)benzoyl]amino}-benzoic acid as a novel antiadenoviral compoundInhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains.Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients.Anti-BK virus activity of nucleoside analogs.Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery.Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses.Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro.Adenoviral nephritis in a renal transplant recipient: Case report and literature review.
P2860
Q24599841-013A7BDF-62A2-4876-81D7-CDD045146190Q27000998-20D1638D-4A08-4D39-ABC6-AB38D97A1CFEQ30457132-04B1AFA9-1206-4DAC-9F15-3AFA256CF8A4Q33804593-01D2C339-64B2-40E0-B1DB-79E2DBD313D9Q33935329-B74D8DFE-D1D6-4C65-B9CE-16EC0D7CBC1DQ34038196-E3351D20-EC59-4FBA-9A6A-534AFC76EA60Q34123729-341076C9-DA71-426F-BCD5-E97A21E26251Q34464655-ED398747-F4D8-4441-B9A8-4508820CE3E4Q34721564-4985A87A-3185-4C2B-83AF-BDF8C840C242Q34801704-B986BC09-23B5-4A2F-91F0-798409D6F8A8Q34973723-DA1D9E09-449C-43B0-A6ED-A21D2CC3DCE6Q35260316-8BAF2D7D-5992-4B9C-BE6E-7E8F99B81DE9Q36185647-2578A238-853D-40E2-86C6-EDA99B5BDA65Q36221367-B21CD249-996D-4DC3-BA24-C87BEA5659A2Q36295406-CC62126E-4950-4E63-B389-DC8F86BCE33EQ36538677-EC5A6C83-88FD-40E2-9EB8-1B5D90CD0E63Q36734750-E98BC0DD-0A48-47B4-A374-5BD2EF580B65Q36900283-82885F81-6C65-43B6-953A-57DF30C269A8Q37069884-4FC43114-3A08-41BD-ACAA-87D36198094BQ37247639-CD4321E4-CC69-43A5-8D94-421F79FC1E74Q37401749-915A9D94-9512-4E05-9177-AAABBC1AE4D4Q37450711-2175A7B9-6B20-4CE4-9A27-47CF18C8ABB0Q37450784-EA36AD13-BEED-4F8B-90A9-03199768EAB9Q37788451-9341DDC9-BBC9-492B-8BF6-E77E0F72CD4CQ37788461-83E2F6CC-E08D-4A64-B5F6-5CB72A053EA8Q37811458-31B852EF-E6DC-4990-A185-3FFB06F44E54Q38005228-D0CFF0F7-A74A-4101-B920-E4A43548F448Q38007145-E87887E9-16F6-4187-A6C2-AF13CE81CF74Q38614278-C504B148-377C-49CD-A74C-7E1FDE8F7604Q39249412-F7ED741F-9741-496E-9FC2-1FF4EFAE07D3Q39424154-48007BB9-C2B8-41BF-97D1-CB5C1BD81D4AQ39687396-A9254B7D-BF84-4915-8762-F39DE3182E07Q39929713-F7EF89C4-8090-4133-949A-5ABA701E3F19Q40147617-3DDBFDB1-1F40-46EA-B900-BE86A65FCD36Q40426465-210ECAED-BB81-4E47-B28B-A6C9FAE1E335Q41826238-0798D1AB-5235-4D8A-828D-F10B9FEC5FD0Q41904300-53B7DC9D-2CB8-4C48-8AF1-F7CEA9553F31Q42200165-F8B1F7B0-267F-47D4-9C5A-2E335A3B34ACQ43261185-DD1AD70D-79E3-436A-940E-838E70A7C27BQ44968033-8FA72954-8451-426F-BB00-25CAE843BD06
P2860
Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Ether lipid-ester prodrugs of ...... enovirus replication in vitro.
@en
Ether lipid-ester prodrugs of ...... enovirus replication in vitro.
@nl
type
label
Ether lipid-ester prodrugs of ...... enovirus replication in vitro.
@en
Ether lipid-ester prodrugs of ...... enovirus replication in vitro.
@nl
prefLabel
Ether lipid-ester prodrugs of ...... enovirus replication in vitro.
@en
Ether lipid-ester prodrugs of ...... enovirus replication in vitro.
@nl
P2093
P356
P1476
Ether lipid-ester prodrugs of ...... enovirus replication in vitro.
@en
P2093
Caroll B Hartline
Earl R Kern
James R Beadle
Karl Y Hostetler
Stephanie L Ciesla
William B Wan
P304
P356
10.1086/426831
P407
P577
2004-12-29T00:00:00Z